Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 103fludarabine 61Methotrexate 49Dexamethasone 46fludarabine phosphate 45Cytarabine 45Vincristine 42blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Mercaptopurine 26Melphalan 26venetoclax 24Specimen Handling 24Etoposide 23Peripheral Blood Stem Cell Transplantation 21pegaspargase 20Stem Cell Transplantation 19Granulocyte Colony-Stimulating Factor 19Calcium Dobesilate 19Busulfan 19Doxorubicin 18Prednisone 17Rituximab 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × AP 1903 reagent × 1 year × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01494103 2025-07-11

DOTTI

Baylor College of Medicine

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Epstein-Barr Virus Infections, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡